



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

28th October 2020

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q2 & FY20-21

Please find enclosed a press release issued by the Company in respect of financial results for the second quarter and half year ended September 30, 2020.

This is for your information and record.

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary



PRESS RELEASE

Wednesday, 28th October 2020, Mumbai

GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2020 EBIDTA Margin @ 23.5%

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 30th September 2020. Revenue for the quarter came in at Rs. 879 crores recording a growth of 3% adjusting for the tail end portfolio rationalization undertaken by the company in 2019. The revenue this quarter also saw a significant recovery clocking a growth of 35% as compared to the quarter ended 30th June 2020. Profit After Tax came in at Rs 77 crores.

Commenting on the results, **Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited** said,

“GSK continues to demonstrate resilience in these times, as we focus our efforts on the safety of our employees while ensuring patients have access to our medicines. This has been reflected in our results for the quarter, wherein sales have grown double digit since Q1 FY21 bouncing back to prior year levels. Most of GSK’s key brands have outpaced their respective categories by gaining market share and our cost reduction/efficiency initiatives have helped drive margin expansion.

We also continued our focus as an innovation-driven, science-led biopharmaceutical company with the recent launch of Fluarix Tetra - the world's first inactivated Quadrivalent Influenza Vaccine during the quarter.

After considering all the strategic options available with the company for its manufacturing site at Vengal following the global voluntary recall of Zinetac, the Company has decided to proceed with the sale of the site and has classified the assets as held for sale.”

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contacts:

Ransom D’Souza

Vice President Corporate Communications and Government Affairs

Email: ransom.a.dsouza@gsk.com